Targeting of B‐cell antigen CD19 to treat acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) has so far produced the most considerable clinical success rates [3], but a variety of other antigens are currently under consideration for targeting of malignant hematologic diseases (Table 1). Here, CD19 is linked to acute lymphoblastic leukemia.